
Article in Japanese
A case in which bone marrow biopsy from the site of metastasis led to identification of the EGFR T790M mutation
Yoshitaka Teia Naoto Mikamia Hiroko Aikob Masaki Yamamotoa Makoto Kudoa Takeshi Kanekoc
aRespiratory Disease Center Internal Medicine, Yokohama City University Medical Center
bRespiratory Medicine, Yokohama Rosai Hospital
cDepartment of Pulmonology, Yokohama City University Graduate School of Medicine
A 70-year-old man had been diagnosed with lung adenocarcinoma cT4N2M1b (multiple bone metastases) with EGFR mutation (exon19 deletion) and received first-line chemotherapy with gefitinib. However, although the primary cancer has been controlled, bone metastasis progressively worsened after one year's chemotherapy. To detect the EGFR T790M mutation which would suggest EGFR-TKI resistance, we performed a bone marrow biopsy from the iliac metastasis site and confirmed the mutation. He was then able to take osimertinib as second-line chemotherapy.
In the present report, we show that a biopsy from the metastasis site in the bone marrow should be considered so as to detect histological findings that may include driver gene mutation.
EGFR-mutant adenocarcinoma Rebiopsy Bone metastasis Marrow biopsy
Received 30 Oct 2018 / Accepted 25 Feb 2019
AJRS, 8(3): 163-166, 2019